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Abstract: Targeting PPIs with small molecules can be
challenging owing to large, hydrophobic binding surfaces.
Herein, we describe a strategy that exploits selective a-helical
PPIs, transferring these characteristics to small molecules. The
proof of concept is demonstrated with the apoptosis regulator
Mcl-1, commonly exploited by cancers to avoid cell death.
Peptide-directed binding uses few synthetic transformations,
requires the production of a small number of compounds, and
generates a high percentage of hits. In this example, about 50%
of the small molecules prepared showed an IC50 value of less
than 100 mm, and approximately 25% had IC50 values below
1 mm to Mcl-1. Compounds show selectivity for Mcl-1 over
other anti-apoptotic proteins, possess cytotoxicity to cancer cell
lines, and induce hallmarks of apoptosis. This approach
represents a novel and economic process for the rapid
discovery of new a-helical PPI modulators.
Protein–protein interactions (PPIs) regulate many processes
in life, both in healthy and disease states,[1] and almost two
thirds of protein–protein interfaces have a-helical binding
motifs.[2] However, targeting PPIs can be difficult owing to
their large hydrophobic binding surfaces.[3] There are cur-
rently three commonly employed approaches to develop
modulators of PPIs:[4] fragment screening,[5] computational
screening and drug design,[6] and the exploration of peptides
and peptidomimetics.[7] However, computational design and
fragment screening require large libraries of molecules and
extensive synthetic work, often resulting in non-selective
compounds.[3] Peptides are challenging drug leads because
in vivo their efficacy can be compromised owing to a loss of
secondary structure, poor cellular uptake, and susceptibility
to proteolysis.[8]
The work described here exploits the advantages of the
above approaches while limiting their weaknesses. This
approach, termed peptide-directed binding, utilizes the tight
and selective binding of a-helical peptides that govern PPIs as
a framework for the discovery of small molecules. Sections of
the natural peptide are employed to identify a small-molecule
fragment that emulates the peptide.
Inspiration for this approach was taken from the
REPLACE strategy of McInnes and co-workers[9] and the
chimeric inhibitors of the 14-3-3/Tau PPI developed by
Ottmann and co-workers.[10] The work also exploits the
advantages of altering peptidic binders, demonstrated by the
groups of Gellman,[11] Fairlie,[12] and Wilson.[13] The technique
demonstrated here improves these strategies by substituting
up to ten amino acids with one small-molecule fragment and
rapidly supplanting the entire peptide chain with a small-
molecule modulator.
In this proof-of-concept study, the a-helical PPI of
Mcl-1 and Noxa, members of the apoptosis-regulating Bcl-2
family of proteins, was employed as an example.[14] Anti-
apoptotic proteins (e.g., Bcl-2, Bcl-xL, and Mcl-1) are often
overexpressed in cancer, contributing to the development of
the tumor and resistance to current therapies.[15]
Noxa displays high selectivity towards Mcl-1.[16] The
NoxaB (NoxaB-(75–93)-C75A) peptide contains the 19
amino acids (AAQLRRIGDKVNLRQKLLN) from the
BH3 binding region of Noxa, and has been shown to bind
tightly as an a-helix in the binding groove of Mcl-1.[17] NoxaB
was divided into amino acids 75–84 (AAQLRRIGD) and 85–
93 (KVNLRQKLLN); each section possesses two key bind-
ing residues (L78, I81, V85, and Q89),[17] and reactive
terminals were attached (Scheme 1A). These peptides pos-
Scheme 1. A) Concept of using peptide-directed binding to target PPIs.
B) Extended NoxaB peptide fragment that demonstrated restored
affinity for Mcl-1.
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sessing reactive terminals displayed no appreciable binding
affinity for Mcl-1 (IC50> 100 mm in a previously reported
competitive fluorescence anisotropy (FA) assay),[16c] in
accordance with results reported by Colman and co-work-
ers.[17] These reactive terminals were then utilized to perform
copper-catalyzed azide–alkyne cycloaddition (CuAAC) reac-
tions to attach small-molecule fragments (R1 and R2).[18] If
binding affinity is restored for these small-molecule/peptide
hybrids (AAQLRRIGD@R1 and R2@KVNLRQKLLN), then
the attached small-molecule fragment may represent a good
emulator for that particular section of NoxaB.
As an initial control for this strategy, the two peptide
fragments were clicked together to generate an extended
NoxaB peptide, which had an IC50 value of 7.23: 0.88 mm,
compared to 650: 130 nm for NoxaB, highlighting the suit-
ability of the approach (Scheme 1B).
To economize peptide-directed binding, covalent docking
studies using the Schrodinger Suite were employed to assist in
the identification of the small-molecule fragments most likely
to mimic a section of the NoxaB peptide. The crystal structure
geometry of the NoxaB peptide with Mcl-1 (PDB No.
2NLA)[17] was modified; virtually, amino acids 85–93 of
NoxaB were removed, and propargylglycine was attached to
the C-terminus of amino acids 75–84. Covalent docking
studies were performed on a catalogue of azides, modelling
a Huisgen cycloaddition (see the Supporting Information for
details). The results were scored and ranked,[19] and those
highly ranked structures that were synthetically and econom-
ically viable were chosen for synthesis. Similarly, amino acids
75–84 of the peptide were virtually removed, and azidoacetic
acid was attached to the N-terminus of amino acids 85–93.
In this manner, we selected sixty hybrid compounds,
which were synthesized and screened for their ability to
disrupt the Mcl-1/Noxa PPI. The peptide consisting of amino
acids 85–93 (KVNLRQKLLN) of NoxaB was prepared by
solid-phase peptide synthesis (SPPS), and azidoacetic acid
was used to cap the peptide (Scheme 2, middle). Subse-
quently, various alkynes were exposed to the peptide on the
resin in the presence of Cu(MeCN)4PF6 and DIPEA in DMF
to achieve CuAAC reactions. The use of an N-coordinated
CuI source was found to be advantageous, as other CuI sources
gave lower yields, presumably owing to sequestration of the
copper catalyst by peptidic coordination. Cleavage from the
resin and reverse-phase HPLC provided a library of 35 R2–
KVNLRQKLLN hybrids. An analogous method was applied
to prepare 25 AAQLRRIGD–R1 hybrids with a propargyl-
glycine-terminated SPPS resin (Scheme 2, top).
The ability of these 60 hybrids to inhibit the interaction of
Mcl-1 and FITC-Noxa was examined in an FA assay; 23
compounds (30%) were identified as hits (defined as having
an IC50< 100 mm). Eight of these hits contained amino acids
75–84, and 13 hits were derived from amino acids 85–93
(Table 1; see also the Supporting Information, Table S1).
The orthogonal nature of the reaction enabled the
combination of azide and alkyne small-molecule fragments
to generate a library of small-molecule triazoles that in theory
have an increased likelihood of possessing characteristics that
emulate the entire NoxaB peptide. The identified hybrid
molecules suggested 104 triazoles for preparation. We
selected 35 for synthesis and evaluated them in an FA assay
(Scheme 2, bottom). Nineteen (54%) of the triazole com-
pounds showed an IC50< 100 mm, and ten (27%) compounds
displayed an IC50< 1 mm (Table 2 and Table S2).
The nature of this approach allows for structure–activity
relationships (SARs) to be drawn without targeting specific
modifications. The most potent compounds, 16 and 17, both
possess a heptyl chain, which provokes concerns about non-
specific hydrophobic events. However, not all of the synthe-
sized compounds with the heptyl chain demonstrated activity
(Table S2). Additionally, the Fmoc-propargylglycine moiety
proved effective in several of the identified binders (18, 20, 21,
23, and 25), but again was not a feature that was sufficient for
binding on its own (Table S2). Concerns over the Fmoc
protecting group were considered, but as these compounds
are primarily meant as chemical probes or potential leads,
further development may discover more effective alterna-
tives. Indeed, the Fmoc group is somewhat reminiscent of
structural features present in SouersQ A-1210477[16d] and
FesikQs 2-indole-acylsulfonamides,[20] which are highly potent
and selective Mcl-1 binders. Interestingly, the most potent
small molecules did not result from the combination of the
most potent small-molecule peptide hybrids 2 and 9, as might
Scheme 2. Synthesis of the small-molecule/peptide hybrids by SPPS and subsequent synthesis of small-molecule peptide mimics. DIPEA=diiso-
propylethylamine, DMF=dimethylformamide, TFA= trifluoroacetic acid, TIPS= triisopropylsilane.
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be expected. The combination of 2 and 9 demonstrated no
appreciable ability to inhibit the interaction of Mcl-1 and
FITC-Noxa. Additionally, the small-molecule fragment of 9
did not appear in any small molecule that inhibited the Mcl-1/
FITC-Noxa interaction. A possible explanation for this
phenomenon is that some small-molecule fragments, when
bound to the peptide fragment, alter the helicity of the
peptide, perhaps increasing the binding affinity of the peptide
segment or altering the binding site.[21] Further studies on the
power of small-molecule/peptide hybrids as PPI modulators
are underway.
It has been shown that NoxaB is a selective Mcl-
1 binder.[17] The deployment of the NoxaB peptide as
a scaffold for discovering new compounds was envisaged to
also impart this selectivity onto the new small-molecule
mimics. To examine this, we employed two in vitro FA assays
with Bcl-2 and Bcl-xL, using an FITC-tagged Bid peptide as
our fluorescent marker.[22] Navitoclax (ABT-263) was
employed as a positive control and as an additional indication
that the FA assay was performing adequately.[16b] Excitingly,
compounds 16–25 and an additional nine compounds (see the
Supporting Information) displayed no appreciable binding to
Bcl-xL or Bcl-2 in our FA assays (Figure 1; see also the
Supporting Information), demonstrating a minimum 20-fold
selectivity for Mcl-1. To confirm that this result was not an
artefact, all compounds were re-examined in the Mcl-1, Bcl-2,
and Bcl-xL assays twice more, with the NoxaB peptide and
Navitoclax performing as expected. These results also provide
some relief about the potential of non-specific hydrophobic
events caused by the heptyl chain or the Fmoc group.
Compounds 16–25 were examined to determine if they
displayed activity towards pancreatic cancer cells, which are
known to overexpress members of the Bcl-2 family, including
Mcl-1. An MTS assay was employed to examine the ability of
the compounds to inhibit cell growth and affect metabolism,
a potential indicator of cell death. Several compounds,
notably 18, 20, 21, 23, and 24, displayed activity towards the
pancreatic cancer cell lines BxPC-3, known to overexpress
Mcl-1, and MiaPaCa-2, which overexpresses both Mcl-1 and
Bcl-2. Interestingly, compound 19 only had activity against
BxPC-3 cells. The pancreatic cancer cell line AsPC-1, which
does not overexpress Mcl-1, was also evaluated (Table 2).
Two compounds, 18 and 21, were ineffective against
AsPC-1 cells at the concentrations evaluated in our assay,
which may suggest that they are acting through the inhibition
of Mcl-1. The difference in the magnitude of activity in cells
compared to the in vitro FA assay is a commonly observed
phenomenon, and largely due to cell permeability.[16d,23]
Indeed, some of the more potent compounds in the FA
assay showed no activity in the cellular assays, such as
compound 17 (IC50= 102: 14 nm), suggesting an inability to
Table 1: IC50 values for inhibition of the binding of FITC-NoxaB to Mcl-1 of small-molecule/peptide hybrids.
[a]
Peptide Small molecule FA IC50 [mm] Peptide Small molecule FA IC50 [mm]
2 AAQLRRIGD 0.4:0.3 9 KVNLRQKLLN 0.1:0.1
3 0.7:0.8 10 1.2:9.5
4 5.8:4.6 11 3.5:1.5
5 <100[b] 12 4.3:0.9
6 <100[b] 13 8.2:1.9
7 <100[b] 14 8.3:3.6
8 <100[b] 15 <100[b]
[a] IC50 values determined by non-linear regression of at least three experiments. Errors are the transformed greater extreme of the standard error.
[b] The hybrid compound displayed an IC50 value of <100 mm and >10 mm, accurate value not determined. Fmoc=9-fluorenylmethylcarbonyl.
Figure 1. Representative titrations of compounds 18 (left) and 21
(right) on 5 nm FITC-NoxaB peptide in the presence of 10 nm Mcl-
1 protein (red) or 5 nm FITC-Bid peptide in the presence of 30 nm Bcl-
2 (yellow) and Bcl-xL (green), demonstrating no appreciable binding to
Bcl-2 and Bcl-xL.
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cross the cell membrane. Additionally, subnanomolar binding
affinities are often required for small molecules to compete
with high-affinity endogenous ligands.[24] Compounds 18, 20,
21, and 23 were highlighted by this assay, and selected for
further examination.
To determine if these compounds are impacting on the
intrinsic apoptosis pathway, as would be expected if they are
binding to Mcl-1 in cells,[25] assays were performed that
demonstrate induction of the apoptosis pathway. Compounds
18, 20, 21, and 23 induced an increase in caspase-3 activation
in BxPC-3 cells 4 h after treatment, as indicated by the
cleavage of DEVD–pNa and a subsequent increase in optical
density at 405 nm.[26] Compounds 18 (25 mm, 0.053: 0.02), 20
(5 mm, 0.036: 0.009), 21 (5 mm, 0.046: 0.004), and 23 (25 mm,
0.139: 0.06) all induced an increase in optical density at
405 nm compared to a vehicle control (DMSO, 0.1%, 0.003:
0.005) in this assay (Figure 2A).
Additionally, compounds 18, 20,
21, and 23 were shown to induce
the externalization of phosphatidyl-
serine on the cell surface,[26] as
demonstrated by the binding of
annexin-V-FLUOS to BxPC-3
cells, resulting in green fluorescence
(Figure 2B).
In conclusion, by utilizing the
selective NoxaB peptide as a frame-
work, a library of novel Mcl-1 bind-
ers that demonstrate selectivity for
Mcl-1 has been prepared. Peptide-
directed binding provided a high
percentage of compounds with
increased potency when compared
to traditional methods of high-
throughput screening, by the appli-
cation of a natural peptide frame-
work and simple synthetic manipu-
lations. Recent literature demon-
strates that fragment-based meth-
ods require the screening of approx-
imately 15000 fragments by NMR
spectroscopy and extensive subse-
quent synthetic manipulations to
generate a selective potent Mcl-
1 binder.[23] Additionally, high-
throughput screening has been
shown to have a hit rate of 0.2%
in recent studies targeting the Bcl-2
family and other prominent cancer
PPIs.[27] The method exemplified
here represents a significant eco-
nomic improvement, in terms of
both cost and time, when compared
to both high-throughput screening
and fragment-based methods and is
a powerful new approach towards
discovering modulators of a-helical
PPIs. A subset of the identified
in vitro binders was found to pos-
sess activity towards cancer cell lines that overexpress Mcl-
1 and induce hallmarks of the apoptosis pathway. It is
important to note that these compounds are currently
unoptimized but still achieved low micromolar cellular
activity, exemplifying the power of peptide-directed binding
to swiftly generate potential selective leads for challenging
targets.
This proof-of-concept study has demonstrated that pep-
tide-directed binding is a technique that rapidly identifies new
leads for a-helical protein–protein interactions, as effectively
exemplified for the Mcl-1/Noxa PPI. Importantly, these
compounds are able to mimic the selectivity of the natural
scaffold. A recent review on Mcl-1 inhibitors highlights that
less than thirty compounds have been reported with com-
parable selectivity for Mcl-1.[28] Further studies are underway
to structurally confirm the binding sites of the hybrid and
Table 2: IC50 values for the inhibition of the binding of FITC-NoxaB to Mcl-1 of small molecules and cell
growth inhibition of representative compounds towards the pancreatic cancer cells lines MiaPaCa-2,
BxPC-3, and AsPC-1.[a]
Compound FA IC50
[nm]
MiaPaCa-2
[mm]
BxPC-3
[mm]
AsPC-1
[mm]
16 33:8 >100 >100 >100
17 102:14 >100 >100 >100
18 186:20 15.19:0.75 29.82:4.15 >100
19 217:58 >100 21.60:8.83 >100
20 249:51 6.57:3.92 5.98:1.14 2.04:0.62
21 1260:142 1.85:3.17 2.81:0.40 >100
22 1680:694 >100 >100 >100
23 1700:230 19.52:1.35 25.21:2.66 10.54:1.53
24 2210:877 2.14:0.56 10.66:2.72 2.28:1.44
25 5500:3923 >100 >100 >100
[a] IC50 values determined by non-linear regression of at least three experiments. Errors are the
transformed greater extreme of the standard error.
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small-molecule compounds generated from peptide-directed
binding. It is expected that peptide-directed binding is
applicable to other a-helical PPIs, such as the p53/hDM2
interaction, the Bcl-xL/BIM interaction, or the HIV gp41
hexameric coiled-coil fusion complex.[29]
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Figure 2. Representative small molecules induce hallmarks of apopto-
sis. A) Increase of caspase-3 activation in BxPC-3 cells 4 h after
treatment. B) Externalization of phosphatidylserine, a hallmark of
apoptosis, was evaluated by exposing BxPC-3 cells to compounds 18
(25 mm), 20 (5 mm), 21 (5 mm), and 23 (25 mm) for 4 h followed by
annexin-V-FLUOS. Images were taken at 10W magnification with a GFP
filter (top) and white light (bottom).
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